Collectively, these results are consistent in showing that the combined cardiac overexpression of IL9, IL3, IL4, IL13, and IL15 during the chronic phase of CVB3-induced VM can significantly improve the outcome of cardiac disease, reducing cardiac dilatation and dysfunction. This evidence concerns the gene IL9 and Vascular dilatation.